Study reveals why many opt out of multiplex testing for cancer-related gene variants
the ONA take:
Many patients do not want the information that comprehensive genetic testing provides, according to a study from researchers at the Perelman School of Medicine at the University of Pennsylvania and the Basser Center for BRCA in Penn’s Abramson Cancer Center.
In the study, 49 patient participants with a family or personal history that increased their risk for developing breast and other forms of cancer were offered multiplex testing. More than one-third of the participants declined the test because of uncertainty of the results.
Multiplex testing allows for simultaneous analysis of alterations in multiple cancer-related genes, whereas targeted testing focuses on a specific genetic mutations (eg, BRCA1 and BRCA2 gene mutations). However, the significance of alterations in many of the genes analyzed in multiplex testing is unknown.
All 49 participants received counseling on the advantages and disadvantages of the tests. After counseling, 16 participants declined multiplex testing or being told their results.
Of the remaining participants, 16 tested negative for any cancer-related variants, five tested positive, and 12 were found to have gene variants of uncertain significance (meaning that whether the changes are benign or tied to cancers is unclear).
Many patients do not want the information that comprehensive genetic testing provides.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|